Antengene Corporation Limited announced on May 20, 2025, a global clinical collaboration with Merck. The collaboration aims to evaluate ATG-022 in combination with KEYTRUDA (pembrolizumab).
This partnership is expected to enhance Merck's oncology portfolio by exploring new combination therapies. ATG-022 is a promising investigational cancer therapy, and its evaluation with Keytruda could lead to new treatment options.
The collaboration underscores Merck's strategy of leveraging external innovation and its blockbuster drug to expand its oncology pipeline. This development is a positive step towards advancing novel cancer treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.